Galectin Therapeutics
1 follower
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pat... Read more
Org chart
Joel Lewis
CEO & President
Joel Lewis
Collapse
Pol F. Boudes
Chief Medical Officer
Susan Thornton
VP, Regulatory Affairs
Ezra R. Lowe
VP, Clinical & Preclinical Pharmacology
Jeff Katstra
Head of CMC & Pharmaceutical Development
Sharisse Brutto
Director, Project Management
Seth Zuckerman
Senior Director, Biostatistics
Teams
View all
